Research Analysts Set Expectations for Vertex Pharmaceuticals Incorporated's Q2 2017 Earnings (VRTX)

Ivan Schwartz
July 19, 2017

With 980,400 avg volume, 5 days are for Assured Guaranty Limited (NYSE:AGO)'s short sellers to cover AGO's short positions.

About 782,635 shares traded. It has outperformed by 45.93% the S&P500.

Rhenman & Partners Asset Management Ab decreased Vertex Pharmaceuticals Inc (VRTX) stake by 18.75% reported in 2016Q4 SEC filing.

The company is trading up since yesterday's close of $129.21. National Pension Service now owns 200,779 shares of the pharmaceutical company's stock valued at $21,542,000 after buying an additional 7,809 shares in the last quarter. T now has $51.00B valuation. Insiders own 1.80% of the company's stock. Another trade for 1,900 shares valued at $162,897 was sold by Chodakewitz Jeffrey.

Now the shares of Vertex Pharmaceuticals Incorporated (VRTX) has the trading volume of 2.75 Million shares with the average trading volume of 1360 shares.

Assured Guaranty Ltd.is a holding company.

Market Capitalization can be thought of as the overall price to buy the company. The Company, through its subsidiaries, provides credit protection products to the United States and global public finance, including infrastructure, and structured finance markets. It has a 186.65 P/E ratio. As per Friday, March 17, the company rating was upgraded by JMP Securities. Therefore 55% are positive. On Friday, July 14 the stock rating was maintained by BMO Capital Markets with "Hold". Mason Street Advsrs Ltd Llc, Wisconsin-based fund reported 33,930 shares. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. He wrote in a July 10 research note that results of that magnitude could drive Vertex's shares above $150 (from $130 at that time; they closed Tuesday at $132.16). Keefe Bruyette & Woods maintained the stock with "Hold" rating in Friday, June 9 report. 26,872 were reported by Kcg. Sachdev Amit sold $13,267 worth of stock.

Apple's iPhone Pro to Cost $1100, JPMorgan Says
Instead, the bank said, Apple's highest-end iPhone will launch on time but will only be available in limited quantities at first. TSMC won't be dumped altogether, though, with the Herald noting that Samsung likely will split production Taiwanese firm.

Leeds United set to bring in Everton defender Matthew Pennington on loan
Leeds have announced the signing of defender Matthew Pennington on a season-long loan from Everton . Pennington has become Leeds' ninth signing of what has been a very busy transfer window to date.

Donald Trump suffers setback on his goal of repealing Obamacare
Elizabeth Warren (D-Mass.) has also implored her fellow Democrats to embrace the idea. Toomey said he is "disappointed with the failure of the draft Senate bill ".

Investors sentiment increased to 1.24 in Q4 2016. 119.74 million shares or 2.02% less from 122.20 million shares in 2016Q3 were reported. The current share price indicates that stock is -3.72% away from its one year high and is moving 84.94% ahead of its 52-week low. First Washington stated it has 73,368 shares. Walleye Trading Limited Liability Company has invested 0.01% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Nordea Invest Management Ab has 140,315 shares for 0.01% of their portfolio. EPS breaks down the profitability of the company on a single share basis. Delta Lloyd Nv reported 25,491 shares. Barclays Capital maintained Cisco Systems, Inc. Bnp Paribas Arbitrage accumulated 109,590 shares. Brick & Kyle owns 150 shares. It also upped Zogenix stake by 734,458 shares and now owns 752,999 shares. Abiomed Inc (NASDAQ:ABMD) was raised too. Vetr raised Vertex Pharmaceuticals from a "strong sell" rating to a "strong-buy" rating and set a $156.00 price objective for the company in a research report on Tuesday. Therefore 63% are positive. Finally, Jefferies Group LLC initiated coverage on Vertex Pharmaceuticals in a report on Monday, July 10th. Upgrade from a "Market Perform " rating to a " Outperform" rating. The company presently has a consensus rating of "Buy" and a consensus target price of $125.39. Leerink Swann now has a "Outperform" rating on the stock. Moreover, Benjamin F Edwards & has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 114 shares.

Since February 1, 2017, it had 0 buys, and 30 selling transactions for $68.81 million activity.

Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. In the last 90 days, insiders have sold 404,097 shares of company stock worth $50,604,479.

Vertex Pharmaceuticals Incorporated (VRTX) opened at 132.16 on Wednesday. The stock was sold at an average price of $127.80, for a total value of $439,376.40.

Investors sentiment decreased to 0.88 in 2016 Q4. Its down 0.22, from 1.1 in 2016Q3. SARIN ARUN sold 13,869 shares worth $472,436. 46 funds opened positions while 141 raised stakes. (NASDAQ:ANGO) was $15.71 and the volume amounted to 0.46 million shares which compares with the average volume of 0.23 million shares. Blackrock Institutional Tru Na holds 6.53M shares. 275.43 million shares or 0.62% less from 277.16 million shares in 2016Q3 were reported. For the last quarter, shares have performed 15.27%. Ibm Retirement Fund stated it has 0.08% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Mitsubishi Ufj Trust And Banking owns 661,205 shares. Capstone Asset Mngmt has invested 0.05% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Gfs Advsr holds 0.72% in JPMorgan Chase & Co. Australia-based Westpac Bk Corp has invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Northeast Financial Consultants Inc invested in 0.79% or 23,971 shares. Vertex Pharmaceuticals accounts for about 0.8% of Blue Sky Asset Management LLC's investment portfolio, making the stock its 18th largest position. Vantage Inv Advisors Ltd owns 200 shares.

A number of other analysts also recently issued reports on the stock. The pharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.09. VRTX's profit will be $11.57 million for 701.54 P/E if the $0.06 EPS becomes a reality.

Currently, EPS of Vertex Pharmaceuticals Incorporated (VRTX) is 0.41 while the analysts predicted the EPS of the stock to be 0.39 suggesting the company fell short of the analysts' expectations.

Other reports by GizPress

Discuss This Article

FOLLOW OUR NEWSPAPER